Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2018
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Amanda J Walker, Laleh Amiri-Kordestani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These DrugsGwynn Ison, Julia A Beaver, W David McGuinn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Michael Brave, Julia A Beaver, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-Associated Advanced Ovarian CancerSanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, et al.Pageof 2